Search hospitals

>

Minnesota

>

Saint Paul

Regions Hospital

Claim this profile

Saint Paul, Minnesota 55101

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

477 reported clinical trials

24 medical researchers

Photo of Regions Hospital in Saint Paul

Summary

Regions Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Regions Hospital is involved with conducting 477 clinical trials across 604 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.

Area of expertise

1

Lung Cancer

Global Leader

Regions Hospital has run 70 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Regions Hospital has run 67 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Regions Hospital

Lung Cancer

Prostate Cancer

Breast Cancer

Breast cancer

Cancer

Colorectal Cancer

Multiple Myeloma

Non-Small Cell Lung Cancer

Ovarian Cancer

Esophageal cancer

Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Regions Hospital?

Where is Regions Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Regions Hospital accept?

What awards or recognition has Regions Hospital received?